Some of the names on the move ahead of the open.» Read More
All week, Cramer's broken down the Dow stock by stock to show Home Gamers how the index should climb another thousand points before the year is over. Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
Big pharma analysts keep close tabs on prescription trends. Many of them issue weekly reports to clients about what's up, what's down, what's holding steady. Investors use the data as a leading indicator for what quarterly sales and profits might look like. So, check out what A.G. Edwards' Joe Tooley is writing in his most recent "Weekly Prescription Trends" report.Tooley titles it, "Lipitor Continues to Decline, Can Simvastatin (the generic version of Zocor) Surpass It?"
Even with a bull market raging on, corporate America is still making like Ebenezer Scrooge when it comes to sharing the wealth with shareholders. Exxon Mobil (XOM), Microsoft (MSFT), Pfizer (PFE) and Cisco (CSCO) are all sitting on more than $20 billion, individually. Shareholders need to start demanding they put this money to work or return it. So which stocks should you buy in anticipation of that?
On Stop Trading! today, Cramer reiterated his bullish stance on the oil drillers. Also, when it comes to tech -- look out below.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
Jeffrey Kindler, the chief executive of drug maker Pfizer Inc., continued to clean house with the announcement late Sunday that the company's research and development chief and chief financial officer will soon leave. John LaMattina, president of global research and development, will retire by the end of the year. Alan Levin, the CFO, also resigned.
This week Cramer is doing a series on CEOs, the best of the best when it comes to company turnarounds. These five executives have turned their once-dead franchises into living, thriving businesses. Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
Joseph Keating, chief investment officer at First American Asset Management, told CNBC’s “Squawk on the Street” that dividend stocks are a good bet in retirement.
French drugmaker Sanofi-Aventis on Thursday reported declining first-quarter profits, citing adverse currency movements, generic competition and a strong quarter in 2006.
Bristol-Myers Squibb's recent agreements with rival drug companies to develop and sell drugs is a signal that the company is committed to staying independent, reports CNBC's David Faber.
Pharmacia and Upjohn Company, a unit of Pfizer, pleaded guilty to one count of offering a kickback to a pharmacy benefit manager and was sentenced to pay a criminal fine of $19.68 million, federal prosecutors said on Wednesday.
The U.S. dollar inched lower Wednesday -- as the euro approached its historic high. What does the transatlantic currency gap mean for America's economy? "Upside surprises," for one thing. David Gilmore, partner at Foreign Exchange Analytics, and Robert Lynch, currency analyst at HSBC, joined "Morning Call" to explain why the ever-weaker dollar may boost parts of the U.S. economy.
Several other major drug companies were apparently interested in buying MedImmune, including Merck, Eli Lilly and possibly Novartis, CNBC’s David Faber reported Tuesday.
M&A news and earnings updates provided some of the catalysts for Monday's most actively traded stocks.
Stocks closed lower as cautious comments from GM and Pfizer snapped the Dow's seven-day winning streak. "We've seen a really good move in the market and a little consolidation is healthy," said Bill Nichols, managing director of equity trading for Bear Stearns. "After being higher so much, a little profit-taking is only natural."
Pfizer said quarterly earnings fell 18%, hurt by one-time charges and anemic sales of inhaled diabetes drug Exubera, plunging demand for drugs facing generic competition. The world's largest drugmaker also warned its 2007 earnings will be below Wall Street expectations due to the unexpectedly swift introduction of cheaper generic forms of its hypertension treatment Norvasc.
What many see as outrageous or obscene compensation for chief executive officers is back in the limelight after some high profile pay packages lately. The contrarian view is that there is little or no direct link between pay and performance and coupling the two might be detrimental because CEOs would cut corners to boost their pay, eroding the company’s long-term prospects.
Johnson & Johnson beat the Street and raised its outlook for this year, but the hybrid Pharma/Consumer Products/Medical Devices company posted a much bigger drop in sales of its highly profitable drug-coated stents than analysts expected. Stents are the expensive, little wire mesh tubes that prop open clogged arteries. Recently, sales of stents coated with drugs have come under increasing scrutiny over safety.
Healthcare giant Johnson & Johnson reported quarterly earnings above Wall Street estimates and raised 2007 earnings guidance, sending shares up almost 3%.
Health care and insurance are two of the fastest-growing segments of the booming pet market. And big drug makers such as Pfizer, Novartis and Eli Lilly have taken note.
The maker of the FluMist vaccine said it was putting istself up for sale, causing its shares to surge more than 10%. MedImmune also said that certain major drugmakers had already indicated they might be interested in a takeover.